Vnitr Lek 2013, 59(3):177-181

Risk factors for diabetic retinopathy

T. Sosna1,2,*, R. ©vancarová1, M. Netuková3
1 Centrum diabetologie IKEM Praha, přednostka prof. MUDr. Terezie Pelikánová, DrSc.
2 Oční oddělení Thomayerovy nemocnice Praha, primář MUDr. Karel Sedláček
3 Oftalmologická klinika 3. lékařské fakulty UK a FN Královské Vinohrady Praha, přednosta prof. MUDr. Pavel Kuchynka, CSc.

Risk factors for diabetic retinopathy can be divided into modifiable and non modifiable. Non modifiable include the type of diabetes, age of the patient at the time of onset, duration, and genetic factors. Primarily it can be influenced by glycemic control, as well as systemic factors such as blood pressure, serum lipids. Concomitant diseases also affect diabetic retinopathy. The article also mentions the risk of rapid compensation and iatrogenic influences.

Keywords: diabetic retinopathy; risk factors; glycosylated hemoglobin; hypertension; dyslipidemia

Received: January 27, 2013; Published: March 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Sosna T, ©vancarová R, Netuková M. Risk factors for diabetic retinopathy. Vnitr Lek. 2013;59(3):177-181.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. ACCORD Study Group; ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363: 233-244. Go to original source... Go to PubMed...
    2. Aiello LP, Gardner TW, King GL et al. Diabetic Retinopathy. Diabetes Care 1998; 21:143-156. Go to original source... Go to PubMed...
    3. Doodson MP. Diabetic Retinopathy. Oxford University Press 2008, 172 s. Go to original source...
    4. Easty DL, Sparrow JM. Oxford textbook of ophthalmology. New York: Oxford University Press 1999, 1308 s.
    5. FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007; 370: 1687-1697. Go to original source... Go to PubMed...
    6. Chantelau E, Eggert H. Acceleration of diabetic retinopathy following improved glycaemic control: a report on 13 cases. Abstract. Diabetologia 1997; 40: (Suppl. 1): A501.
    7. Klein R, Klein BEK, Moss SE et al. Is blood pressure a predictor of the incidence or progression of diabetic retinopathy? Arch Intern Med 1989; 149: 2427-2432. Go to original source...
    8. Klein R, Klein BEK, Moss. SE The Wisconsin epidemiological study of diabetic retinopathy: a review. Diabet Metab Rev 1989; 5: 559-570. Go to original source... Go to PubMed...
    9. Kuchyňka P et al. Oční lékařství. Praha: Grada 2007, 768 s.
    10. Marshall G, Garg SK, Jackson WE et al. Factors influencing the onset and progression of diabetic retinopathy in subjects with insulin-dependent diabetes mellitus. Ophthalmology 1993; 100: 1133-1139. Go to original source... Go to PubMed...
    11. Murphy RP. Management of diabetic retinopathy. Am Fam Physician 1995; 51: 785-796. Go to PubMed...
    12. Pelikánová T, Bartoą V. Praktická diabetologie. Praha: Maxdorf 2010, 738 s.
    13. Pickup J, Williams G. Textbook of diabetes. Oxford: Blackwell Science Ltd. 1997.
    14. Ryan J. Retina. St. Louise: Mosby Inc. 2001, 1847 s.
    15. Scanlon P, Aldington S, Wilkinson Ch et al. Practical Manual of Diabetic Retinopathy Management Wiley-Blackwel 2009, 232 s. Go to original source...
    16. Sosna T, Bouček P, Fiąer I. Diabetická retinopatie - diagnostika, prevence, léčba. Praha: J. Cendelín 2001, 255 s.
    17. The EURODIAB IDDM Complications Study. Retinopathy and vision loss on insulin-dependent diabetes in Europe. Ophthalmology 1997; 104: 252-260. Go to original source... Go to PubMed...
    18. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865. Go to original source...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.